Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes mellitus (T2DM) has become one of the leading causes of morbidity and mortality in developed countries. Low efficacy, weight gain, and hypoglycemia are the main pitfalls of previous treatments for T2DM. New therapies have been designed with the aim of improving the results in efficacy and quality of life. Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1 RA) increase glucose-dependent insulin secretion, decrease gastric emptying, and reduce postprandial glucagon secretion. The last GLP-1 RA approved by the US Food and Drug Administration and European Medicines Agency was semaglutide. This review describes its pharmacology, core clinical data coming from the randomized controlled trials included in the development program, proven cardiovascular benefits, safety issues, and precautions for the use of semaglutide in special populations. Additionally, an overview of the positioning of semaglutide in T2DM therapy and practical issues regarding semaglutide initiation are offered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s002 · Cited by 4,792
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · cited 8×
“Obesity is a key factor in the etiology of the T2DM.”
ResultInfluential2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159
Kassebaum, N. J., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, J., Carter, A., Casey, D. C., Charlson, F. J., Coates, M. M., Coggeshall, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31460-x · Cited by 2,163
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · cited 1×
“Pharmacology and characteristics of the device The efficacy and safety demonstrated by liraglutide were the basis for the development of semaglutide.(13) After testing several molecules, in search of increasing their half-life to achieve a more convenient dosage, semaglutide was chosen.”
BackgroundSorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745 · cited 1×
“31 26 With the exception of SUSTAIN 1 trial, 21 which included subjects without prior treatment and with relatively short duration T2DM, and SUSTAIN 7 trial (comparing dulaglutide), both dose levels of semaglutide were associated with significant reductions in SBP vs the comparator: - 2.4 to - 5.1…”
BackgroundInfluentialDiabetes and hypertension: a position statement by the American Diabetes Association
de Boer, I. H., Bangalore, S., Benetos, A., Davis, A. M., Michos, E. D., Muntner, P., Rossing, P., Zoungas, S., & Bakris, G. (2017) · Diabetes Care · doi:10.2337/dci17-0026 · Cited by 714
Cited by
Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases
Grieco, M., Giorgi, A., Gentile, M. C., d’Erme, M., Morano, S., Maras, B., & Filardi, T. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01112 · Cited by 218
“6 times higher affinity with albumin than liraglutide (Gomez-Peralta and Abreu, 2019).”
BackgroundInfluentialMahapatra, M. K., Karuppasamy, M., & Sahoo, B. M. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09699-1 · Cited by 166
Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide
Gallwitz, B., & Giorgino, F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645507 · Cited by 70
Anyiam, O., Phillips, B., Quinn, K., Wilkinson, D., Smith, K., Atherton, P., & Idris, I. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.06.034 · Cited by 40
Metadata
- Authors
- Gomez-Peralta, F., & Abreu, C.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2019-02
- Volume
- Volume 13
- Pages
- 731-738
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W2917493414
- Cited by
- 27
- References
- 20
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy. https://app.cochat.ai/papers/10.2147/dddt.s165372
- The paper
- Gomez-Peralta, F., & Abreu, C. (2019). Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s165372
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.